La catena delle opzioni mostra i dati chiave delle opzioni azionarie di TriSalus Life Sciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per TriSalus Life Sciences..

TriSalus Life Sciences (NASDAQ:TLSI) Azioni, Catena delle Opzioni

TriSalus Life Sciences

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences Inc

RBC Capital analyst Brad Heffern maintains UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) with a Sector Perform and lowers the price target from $46 to $45.

News

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on UDR, Lowers Price Target to $45

As blockchain technology gains traction in traditional finance, Anthony Rousseau, TradeStation's vice president and head of brokerage solutions, shared his thoughts on the complexities of merging these systems. In a pre-event interview for the upcoming <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets conference</a>, Rousseau detailed the careful process of integrating blockchain within long-established financial structures.
<h3 class="wp-block-heading">A Careful Transition for Traditional Institutions</h3>
Rousseau, who previously worked with State Street's digital assets strategy team, described how traditional financial institutions are cautious in their approach to blockchain. 
"Large financial institutions prioritize identifying and mitigating threats to their current structures while adapting new industries to fit within existing regulatory frameworks," he explained. He noted that the demand for regulated digital asset options among retail investors has grown, signaling a shift toward blockchain adoption.
<figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/04195223/905735A6-57D3-4874-9AA1-75D037842DB3-1-7.gif" alt="" class="wp-image-629106" /></a></figure>
<h3 class="wp-block-heading">The Challenges of Compliance and Compatibility</h3>
Incorporating decentralized technology within conventional finance poses challenges, particularly around regulatory compliance and internal risk systems. 
"Significant challenges remain, including ensuring regulatory compliance and integrating decentralized elements with established risk and reporting systems," Rousseau remarked.
The structure of traditional finance, refined over decades, depends heavily on operational consistency, which makes the shift to transparency and decentralized control an intricate process.
<h3 class="wp-block-heading">Looking Toward the Future</h3>
Rousseau noted that this transformation will not happen overnight. 
"Traditional finance&#8230; has spent decades building business models around the inefficiencies of current structures," he said.
A true shift toward a model of individual ownership, supported by blockchain, "will likely take decades to take shape." While slow, he acknowledged that this evolution could lead to lasting changes in the industry.
As the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets event</a> approaches, Rousseau's perspective brings a thoughtful angle to the ongoing discussion of blockchain's role in reshaping finance while preserving structural integrity.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field.&nbsp;<a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a>&nbsp;event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

Will Blockchain's Move Into Finance 'Take Decades To Take Shape'?

RBC Capital analyst Ken Herbert reiterates V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) with a Outperform and maintains $70 price target.

Reiteration

RBC Capital Reiterates Outperform on V2X, Maintains $70 Price Target

WIIM

ANDE

Andersons shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Intrepid Potash shares are trading higher after the company reported better-than-expected Q3 financial results.

Earnings

PLMR

CORRECTION: Palomar Hldgs Q3 2024 Adj. EPS $1.23 Beats $1.03 Estimate, Net Earned Premiums $135.646M

NMRA

Neumora Therapeutics shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and cut its price target from $18 to $15.

PRIM

Primoris Services shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates.

GLRE

Greenlight Capital Re shares are trading higher after the company reported better-than-expected Q3 financial results.

Piper Sandler analyst Jessica Tassan reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $392 to $394.

Piper Sandler Reiterates Overweight on Cigna, Raises Price Target to $394

SGMO

Sangamo Therapeutics shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $5 to $10.

AGCO Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) shares slipped after the company reported worse-than-expected third-quarter results and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41741857/agco-reports-third-quarter-results" rel="noreferrer noopener">lowered its 2024 outlook.</a>
AGCO reported a third-quarter net sales decline of 24.8% year over year to $2.599 billion, missing the consensus of $2.90 billion.
Regional Sales: South America -47% YoY, Europe/Middle East -18.2% YoY, North America -21.8% YoY, and Asia/Pacific/Africa -11.7% YoY.
Adjusted operating income slid 67% year over year to $143.8 million, and the margin contracted by 710 bps to 5.5%. The gross profit declined 35.4% year-over-year to $603.1 million, and the margin declined 383 bps to 23.2%.
The company reported regional operating margin performance with EME at 6.4%, North America at 7.2%, South America at 11.8%, and APA at 3.8%.
Adjusted EPS of $0.68, down from $3.97 a year ago, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missing the consensus of $1.08.</a>
AGCO&#8217;s cash used in operating activities for the nine months ended September was $108 million, down from cash provided of $202.7 million a year ago. As of September 30, cash and equivalents stood at $642.6 million.
&#8220;We continue to execute against our Farmer-First strategy focused on enhancing profitability through the cycle with our three high-margin initiatives, recent portfolio moves and aggressive actions to control expenses including our ongoing restructuring program,&#8221; said Eric&nbsp;Hansotia, AGCO&#8217;s Chairman, President and Chief Executive Officer.
&#8220;The reaffirmation of our full-year adjusted operating margin&nbsp;outlook&nbsp;of&nbsp;9%&nbsp;underscores this transformation, especially considering the significant market downturn in the&nbsp;third quarter. Low commodity prices and high input costs led to increased conservatism from our dealers and farmers resulting in ongoing production cuts to help reduce AGCO and dealer inventories.&#8221;
The company&#8217;s regular quarterly dividend of $0.29 per common share will be paid on December 16 to all stockholders of <a href="https://www.benzinga.com//node/41528553">record as of the close of business on November 15.</a>
2024 Outlook, lowered: The agricultural machinery maker now expects net sales of $12 billion (prior $12.5 billion) versus the $12.445 billion consensus, <a href="https://www.benzinga.com/calendars/guidance">reflecting lower sales volumes.</a>
AGCO now expects adjusted EPS of ~$7.50 (prior $8.00) versus the consensus of $7.93. The company reaffirms its adjusted&nbsp;operating margin expectation of ~9%.
Price Action: AGCO shares are trading lower by 10.4% at $87.66 at the last check Tuesday.

Equities

Guidance

Movers

AGCO

AGCO Shares Drop As Q3 Results Miss Expectations, 2024 Outlook Cut Amid Softened Global Demand

HighPeak Energy shares are trading higher after the company reported better-than-expected Q3 financial results.

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Tuesday.
Shares of Emerson Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) rose sharply during Monday's session after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above estimates. Also, the company announced it increased return of capital to shareholders with plans to repurchase <a href="https://www.benzinga.com/news/earnings/24/11/41748679/emerson-electric-gains-on-q4-earnings-beat-and-fy25-growth-forecast-eyes-aspentech-buyout">approximately $2B in FY25.</a>
Net sales growth of 13% year over year to $4.62 billion, beating the consensus of $4.57 billion. Underlying sales were up 4%, and underlying orders increased by 2% in the quarter. Adjusted EPS improved 15% to $1.48, beating the consensus of $1.47.
Emerson Electric shares jumped 6.6% to $117.01 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Vimeo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) shares jumped 42.7% to $6.86 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter sales guidance above estimates.</li>
<li>Gogo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) gained 29.3% to $8.47 after the company reported better-than-expected third-quarter financial results.</li>
<li>Astera Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) rose 29.1% to $90.14 after the company reported better-than-expected third-quarter EPS and sales.</li>
<li>Aris Water Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) gained 25.8% to $20.84 following strong quarterly results.</li>
<li>Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) gained 22.4% to $50.70 after the company reported better-than-expected third-quarter financial results and issued guidance above consensus estimates.</li>
<li>UFP Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) rose 20.7% to $335.00 after the company reported better-than-expected third-quarter financial results.</li>
<li>Lindblad Expeditions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) gained 20.6% to $11.28 after the company reported better-than-expected third-quarter financial results.</li>
<li>DXP Enterprises Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) gained 18.7% to $60.45 following strong quarterly results.</li>
<li>Century Aluminum Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) gained 17.7% to $20.66 following upbeat quarterly earnings.</li>
<li>Payoneer Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) climbed 16% to $9.88 after the company reported better-than-expected quarterly EPS and sales and raised its FY24 revenue guidance.</li>
<li>Cushman &amp; Wakefield PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>) gained 13.2% to $14.88 after the company reported better-than-expected quarterly adjusted EPS results.</li>
<li>Ingredion Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) rose 12.6% to $150.97 following upbeat earnings.</li>
<li>Primoris Services Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) gained 10.5% to $71.11 following strong quarterly earnings.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) rose 9.1% to $293.34.</li>
<li>Cummins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) gained 8.7% to $353.91 after the company reported better-than-expected third-quarter financial results.</li>
<li>Nomura Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMR#NYSE">NMR</a>) rose 7.3% to $5.64 following second-quarter results.</li>
<li>Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) gained 6.8% to $149.00 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Intraday Update

Markets

Trading Ideas

ALAB

ARIS

CENX

DXPE

GOGO

INGR

LIND

PAYO

PLTR

POWL

UFPT

VMEO

Emerson Electric Posts Better-Than-Expected Results, Joins Palantir Technologies, DXP Enterprises, Cummins, Apollo Global Management And Other Big Stocks Moving Higher On Tuesday

<h3>Gainers</h3>
<ul>
<li>ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) shares moved upwards by 27.6% to $0.67 during Tuesday's regular session. The market value of their outstanding shares is at $74.3 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lindblad Expeditions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) shares rose 21.55% to $11.37. The market value of their outstanding shares is at $617.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) stock rose 21.21% to $1.6. The market value of their outstanding shares is at $66.7 million. </li>
<li>Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) stock increased by 13.64% to $4.21. The company's market cap stands at $129.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Bowlero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOWL#NYSE">BOWL</a>) stock rose 11.51% to $11.57. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) shares increased by 10.71% to $1.35. The company's market cap stands at $8.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) shares decreased by 13.8% to $3.1 during Tuesday's regular session. The company's market cap stands at $30.5 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) stock decreased by 11.0% to $0.84. The market value of their outstanding shares is at $90.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares fell 10.02% to $1.27. The market value of their outstanding shares is at $133.2 million. </li>
<li>Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) shares decreased by 9.02% to $120.86. The company's market cap stands at $7.0 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares fell 8.96% to $0.91. The company's market cap stands at $22.1 million. </li>
<li>Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) stock decreased by 8.19% to $87.82. The company's market cap stands at $9.7 billion. The company's, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFAM

BOWL

CNTY

HOFV

JDZG

LVLU

PRPL

TDUP

WYNN

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares moved upwards by 147.2% to $0.18 during Tuesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares moved upwards by 143.67% to $0.47. The market value of their outstanding shares is at $6.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares increased by 35.16% to $2.46. The company's market cap stands at $2.6 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares moved upwards by 29.29% to $38.75. The market value of their outstanding shares is at $270.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock increased by 19.42% to $2.09. The company's market cap stands at $54.3 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 18.29% to $0.76. The market value of their outstanding shares is at $29.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares decreased by 39.9% to $0.86 during Tuesday's regular session. The company's market cap stands at $36.6 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 29.9% to $1.97. The market value of their outstanding shares is at $3.6 million. </li>
<li>ATI Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#NYSE">ATIP</a>) stock fell 20.49% to $4.09. The market value of their outstanding shares is at $18.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) shares decreased by 19.06% to $11.1. The company's market cap stands at $722.1 million. The company's, Q3 earnings came out today. </li>
<li>Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares decreased by 18.09% to $3.08. The market value of their outstanding shares is at $685.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock declined by 15.56% to $1.9. The market value of their outstanding shares is at $36.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATHA

ATIP

BJDX

BNOX

NOTV

NUWE

SANA

SMLR

VRCA

ZVSA

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) stock moved upwards by 129.5% to $9.25 during Tuesday's regular session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) stock increased by 26.26% to $20.91. The market value of their outstanding shares is at $639.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agrify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) shares rose 24.84% to $3.92. The market value of their outstanding shares is at $5.2 million. </li>
<li>Li-Cycle Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) stock moved upwards by 22.71% to $3.35. The company's market cap stands at $77.7 million. </li>
<li>DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) shares rose 20.64% to $61.43. The company's market cap stands at $969.9 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares increased by 17.45% to $3.23. The market value of their outstanding shares is at $48.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) shares declined by 28.5% to $10.11 during Tuesday's regular session. The market value of their outstanding shares is at $854.5 million. The company's, Q3 earnings came out yesterday. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock decreased by 23.27% to $5.18. The company's market cap stands at $155.2 million. </li>
<li>Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) shares decreased by 22.4% to $5.89. The market value of their outstanding shares is at $268.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) shares fell 21.76% to $2.41. The company's market cap stands at $83.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) shares declined by 18.12% to $51.33. The market value of their outstanding shares is at $898.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) stock declined by 15.04% to $0.25. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGFY

CVGI

EFSH

HDSN

JELD

LICY

VSTE

WLGS

ZCAR

12 Industrials Stocks Moving In Tuesday's Intraday Session

Upstream shares are trading higher after multiple firms initiated coverage on the stock with an Overweight rating.

<h3>Gainers</h3>
<ul>
<li>Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares increased by 28.4% to $89.41 during Tuesday's regular session. The company's market cap stands at $14.0 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock moved upwards by 25.94% to $2.67. The company's market cap stands at $61.8 million. </li>
<li>8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) shares rose 25.0% to $2.9. The company's market cap stands at $372.1 million. The company's, Q2 earnings came out yesterday. </li>
<li>Brightcove (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>) shares increased by 23.83% to $2.65. The company's market cap stands at $118.6 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares rose 22.65% to $50.79. The market value of their outstanding shares is at $113.7 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) shares increased by 22.44% to $3.35. The market value of their outstanding shares is at $306.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) stock decreased by 23.3% to $1.24 during Tuesday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) shares declined by 22.45% to $0.19. The company's market cap stands at $3.5 million. </li>
<li>Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) stock decreased by 20.41% to $26.47. The company's market cap stands at $767.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) stock declined by 13.01% to $29.04. The market value of their outstanding shares is at $2.8 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) stock fell 11.84% to $2.3. The company's market cap stands at $422.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) stock fell 9.0% to $0.97. The company's market cap stands at $27.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AOSL

BCOV

EGHT

IDAI

NVNI

NVTS

ORKT

PRSO

12 Information Technology Stocks Moving In Tuesday's Intraday Session

RBC Capital analyst Luca Issi maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Sector Perform and lowers the price target from $8 to $5.

EDIT

RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $5

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on TriSalus Life Sciences (TLSI – Research Report),...

TriSalus Life Sciences: Strong Buy on Warrant Exchange Success and Anticipated Technical Rebound

TriSalus Life Sciences (TLSI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William P...

TriSalus Life Sciences: A Comprehensive Analysis of Commercial Success and Promising Drug Pipeline Prospects

TriSalus Life Sciences GAAP EPS of -$0.21, revenue of $7.4M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TriSalus Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlsi-stock-quote/">TLSI</a>) just reported results for the second quarter of 2024.<ul><li>TriSalus Life Sciences reported earnings per share of -21 cents. This was above the analyst estimate for EPS of -49 cents.</li><li>The company reported revenue of $7.36 million.</li><li>This was 6.88% better than the analyst estimate for revenue of $6.89 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tlsi-stock-earnings-trisalus-life-sciences-for-q2-of-2024/">TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024

TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript

Buy Rating Affirmed on TriSalus Life Sciences Amid Strong Financials and Strategic Growth Initiatives

JonesTrading analyst Justin Walsh has reiterated their bullish stance on TLSI stock, giving a Buy rating yesterday. Justin Walsh has given his Buy ...

TriSalus Life Sciences: Outperforming Expectations with a Buy Rating Despite Adjusted Price Target

Maxim Group analyst Jason McCarthy maintained a Buy rating on TriSalus Life Sciences (TLSI – Research Report) yesterday and set a price target of $...

TriSalus Life Sciences: A Strong Buy on Robust Revenue Growth and Promising Clinical Advancements

Northland analyst Carl Byrnes initiated coverage of TriSalus Life Sciences (TLSI) with an Outperform rating and $12.50 price target Published first...

TriSalus Life Sciences initiated with an Outperform at Northland

TriSalus Life Sciences files to sell 10.59M shares of common stock for holders

TLSI

TLSIW

Press Releases

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

TriSalus Reports Q2 2024 Financial Results and Business Update

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Comments

TriSalus Life Sciences

TriSalus Life Sciences (TLSI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO